Trientine

Summary

Trientine (CHEMBL609) is an approved small-molecule copper chelator (ATC A16AX12); indicated across 4 conditions including wilson disease and hypertrophic cardiomyopathy.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: A16AX12
• Indications: 4 conditions
• Clinical trials: 5
• Chemistry: 146.23 Da · C6H18N4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL609
Name	Trientine
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	5565
ChEBI	CHEBI:39501
ATC	A16AX12
Molecular formula	C6H18N4
Molecular weight	146.23
InChIKey	VILCJCGEZXAXTO-UHFFFAOYSA-N

SMILES: C(CNCCNCCN)N

IUPAC name: N’-[2-(2-aminoethylamino)ethyl]ethane-1,2-diamine

ChEBI definition: A polyazaalkane that is decane in which the carbon atoms at positions 1, 4, 7 and 10 are replaced by nitrogens.

Pharmacological roles (ChEBI): copper chelator.

Also known as: NSC-443, Trethylenetetramine, Trientina, Trientine, Triethylene tetraamine, Triethylene tetramine, triethylenetetramine, SID17389525, SID144204713, SID144208264, SID170465257, Triethylenetetramine

Parent form; salt/anhydrous children: CHEMBL1200783, CHEMBL3989777, CHEMBL5095420

Patent coverage: 46,819 distinct patent families (120,457 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 16 (assay-derived). Sample: Tyrosyl-DNA phosphodiesterase 1, Prelamin-A/C, Carbonic anhydrase 2, Carbonic anhydrase 13, Carbonic anhydrase 7, Carbonic anhydrase 1, Carbonic anhydrase 3, Polyunsaturated fatty acid lipoxygenase ALOX15, Carbonic anhydrase 6, Carbonic anhydrase 12.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 16 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
LMNA	6.3	Potency	501.2	nM	CHEMBL_ACT_3650444
ALOX15	5	Potency	10000	nM	CHEMBL_ACT_4464641

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
Wilson disease	3	MONDO:0010200	MONDO:0010200
hypertrophic cardiomyopathy	2	MONDO:0005045	EFO:0000538
melanoma	1	MONDO:0005105	EFO:0000756
neoplasm	1	MONDO:0005070	MONDO:0004992

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE1	2
PHASE3	1
PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00004339	PHASE3	COMPLETED	Study of Tetrathiomolybdate in Patients With Wilson Disease
NCT04706429	PHASE2	COMPLETED	The Efficacy and Mechanism of Trientine in Patients With Hypertrophic Cardiomyopathy
NCT01178112	PHASE1	COMPLETED	Trientine and Carboplatin in Advanced Malignancies
NCT02068079	PHASE1	WITHDRAWN	A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma
NCT03299829	Not specified	COMPLETED	A Retrospective Study to Assess the Clinical Efficacy and Safety of Trientine in Wilson’s Disease Patients

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).